Currently, the phase III EMBER-3 trial (NCT04975308) is evaluating the effectiveness of imlunestrant with or without abemaciclib in comparison to fulvestrant or exemestane, for the treatment of hormone-sensitive advanced breast cancer following progression on aromatase inhibitors. Here, CYP19A1 is linked to breast cancer.